Skip to Main Content

Paper Details

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity.
Nat Cancer
42
2021
AP-1, Activator Protein-1, CDK4/6, breast cancer, breast cancer enhancer landscape, cancer, cancer cell, cancer cell chromatin, cyclin-dependent kinases 4 and 6, endogenous retroviral elements, enhancers, interferon, interferon-driven genes, mouse, super-enhancers
Author NameAffiliation
Len TaingCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Clifford A MeyerCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Bogdan PasaniucDavid Geffen School of Medicine, University of California Los Angeles
Bogdan PasaniucDavid Geffen School of Medicine, University of California Los Angeles
Matthew L FreedmanCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Matthew L FreedmanDana-Farber Cancer Institute
Matthew L FreedmanCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Matthew L FreedmanDana-Farber Cancer Institute
Cynthia X MaWashington University School of Medicine
Matthew J EllisBaylor College of Medicine
Ian E KropDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Myles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Myles BrownDana-Farber Cancer Institute
Jean J ZhaoDana-Farber Cancer Institute
Jean J ZhaoHarvard Medical School
Jean J ZhaoThe Broad Institute of MIT and Harvard
  • 1 - 17

Datasets

Release 1.2